Somatostatin receptor imaging in cns tumours using111IN-octreotide

C. L. Maini, R. Sciuto, A. Tofani, A. Ferraironi, C. M. Carapella, E. Occhipinti, M. Mottolese, M. Crecco

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

This study evaluates the in vivo visualization of somatostatin (SS) receptors in central nervous system (CNS) tumours using111In-octreotide imaging and discusses the clinical implications. Ninety-five patients with histologically confirmed diagnosis of CNS tumours were imaged 2-4 and 24 h after the intravenous injection of 111-185 MBq of111In-octreotide. An uptake index was computed using tumourz non-tumour ratios evaluated using a standard region-of-interest method. Semi-quantitative immuno- histochemical studies of SS binding sites were performed on frozen tumour sections. All meningiomas, most pituitary adenomas and many glial tumours showed a positive scan, whereas all neurinomas, craniopharingiomas and ependymomas had negative receptor scans. Radio-octreotide uptake varied among the SS receptor positive CNS tumours: Very intense in meningioma, intermediate in pituitary adenoma and of a low grade in glioma. The results of immunohistochemical studies confirmed the scintigraphic findings in all cases. We believe111In-octreotide is a suitable radiopharmaceutical for characterizing CNS tumours in vivo as SS receptor positive or negative. This new neuronuclear imaging technique may be useful for differential diagnosis in selected cases, for post- surgical follow-up and in the assessment of differentiation in glial tumours.

Original languageEnglish
Pages (from-to)756-766
Number of pages11
JournalNuclear Medicine Communications
Volume16
Issue number9
Publication statusPublished - 1995

Fingerprint

Central Nervous System Neoplasms
Somatostatin Receptors
Octreotide
Pituitary Neoplasms
Meningioma
Neuroglia
Neoplasms
Ependymoma
Radiopharmaceuticals
Neurilemmoma
Frozen Sections
Somatostatin
Radio
Glioma
Intravenous Injections
Differential Diagnosis
Binding Sites

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Maini, C. L., Sciuto, R., Tofani, A., Ferraironi, A., Carapella, C. M., Occhipinti, E., ... Crecco, M. (1995). Somatostatin receptor imaging in cns tumours using111IN-octreotide. Nuclear Medicine Communications, 16(9), 756-766.

Somatostatin receptor imaging in cns tumours using111IN-octreotide. / Maini, C. L.; Sciuto, R.; Tofani, A.; Ferraironi, A.; Carapella, C. M.; Occhipinti, E.; Mottolese, M.; Crecco, M.

In: Nuclear Medicine Communications, Vol. 16, No. 9, 1995, p. 756-766.

Research output: Contribution to journalArticle

Maini, CL, Sciuto, R, Tofani, A, Ferraironi, A, Carapella, CM, Occhipinti, E, Mottolese, M & Crecco, M 1995, 'Somatostatin receptor imaging in cns tumours using111IN-octreotide', Nuclear Medicine Communications, vol. 16, no. 9, pp. 756-766.
Maini, C. L. ; Sciuto, R. ; Tofani, A. ; Ferraironi, A. ; Carapella, C. M. ; Occhipinti, E. ; Mottolese, M. ; Crecco, M. / Somatostatin receptor imaging in cns tumours using111IN-octreotide. In: Nuclear Medicine Communications. 1995 ; Vol. 16, No. 9. pp. 756-766.
@article{d0e270b1b91644539989bcfafc36c75c,
title = "Somatostatin receptor imaging in cns tumours using111IN-octreotide",
abstract = "This study evaluates the in vivo visualization of somatostatin (SS) receptors in central nervous system (CNS) tumours using111In-octreotide imaging and discusses the clinical implications. Ninety-five patients with histologically confirmed diagnosis of CNS tumours were imaged 2-4 and 24 h after the intravenous injection of 111-185 MBq of111In-octreotide. An uptake index was computed using tumourz non-tumour ratios evaluated using a standard region-of-interest method. Semi-quantitative immuno- histochemical studies of SS binding sites were performed on frozen tumour sections. All meningiomas, most pituitary adenomas and many glial tumours showed a positive scan, whereas all neurinomas, craniopharingiomas and ependymomas had negative receptor scans. Radio-octreotide uptake varied among the SS receptor positive CNS tumours: Very intense in meningioma, intermediate in pituitary adenoma and of a low grade in glioma. The results of immunohistochemical studies confirmed the scintigraphic findings in all cases. We believe111In-octreotide is a suitable radiopharmaceutical for characterizing CNS tumours in vivo as SS receptor positive or negative. This new neuronuclear imaging technique may be useful for differential diagnosis in selected cases, for post- surgical follow-up and in the assessment of differentiation in glial tumours.",
author = "Maini, {C. L.} and R. Sciuto and A. Tofani and A. Ferraironi and Carapella, {C. M.} and E. Occhipinti and M. Mottolese and M. Crecco",
year = "1995",
language = "English",
volume = "16",
pages = "756--766",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Somatostatin receptor imaging in cns tumours using111IN-octreotide

AU - Maini, C. L.

AU - Sciuto, R.

AU - Tofani, A.

AU - Ferraironi, A.

AU - Carapella, C. M.

AU - Occhipinti, E.

AU - Mottolese, M.

AU - Crecco, M.

PY - 1995

Y1 - 1995

N2 - This study evaluates the in vivo visualization of somatostatin (SS) receptors in central nervous system (CNS) tumours using111In-octreotide imaging and discusses the clinical implications. Ninety-five patients with histologically confirmed diagnosis of CNS tumours were imaged 2-4 and 24 h after the intravenous injection of 111-185 MBq of111In-octreotide. An uptake index was computed using tumourz non-tumour ratios evaluated using a standard region-of-interest method. Semi-quantitative immuno- histochemical studies of SS binding sites were performed on frozen tumour sections. All meningiomas, most pituitary adenomas and many glial tumours showed a positive scan, whereas all neurinomas, craniopharingiomas and ependymomas had negative receptor scans. Radio-octreotide uptake varied among the SS receptor positive CNS tumours: Very intense in meningioma, intermediate in pituitary adenoma and of a low grade in glioma. The results of immunohistochemical studies confirmed the scintigraphic findings in all cases. We believe111In-octreotide is a suitable radiopharmaceutical for characterizing CNS tumours in vivo as SS receptor positive or negative. This new neuronuclear imaging technique may be useful for differential diagnosis in selected cases, for post- surgical follow-up and in the assessment of differentiation in glial tumours.

AB - This study evaluates the in vivo visualization of somatostatin (SS) receptors in central nervous system (CNS) tumours using111In-octreotide imaging and discusses the clinical implications. Ninety-five patients with histologically confirmed diagnosis of CNS tumours were imaged 2-4 and 24 h after the intravenous injection of 111-185 MBq of111In-octreotide. An uptake index was computed using tumourz non-tumour ratios evaluated using a standard region-of-interest method. Semi-quantitative immuno- histochemical studies of SS binding sites were performed on frozen tumour sections. All meningiomas, most pituitary adenomas and many glial tumours showed a positive scan, whereas all neurinomas, craniopharingiomas and ependymomas had negative receptor scans. Radio-octreotide uptake varied among the SS receptor positive CNS tumours: Very intense in meningioma, intermediate in pituitary adenoma and of a low grade in glioma. The results of immunohistochemical studies confirmed the scintigraphic findings in all cases. We believe111In-octreotide is a suitable radiopharmaceutical for characterizing CNS tumours in vivo as SS receptor positive or negative. This new neuronuclear imaging technique may be useful for differential diagnosis in selected cases, for post- surgical follow-up and in the assessment of differentiation in glial tumours.

UR - http://www.scopus.com/inward/record.url?scp=0029050972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029050972&partnerID=8YFLogxK

M3 - Article

C2 - 7478408

AN - SCOPUS:0029050972

VL - 16

SP - 756

EP - 766

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 9

ER -